女性間質性膀胱炎患者潰瘍病變與泌尿道微生物菌相分佈相關性

李明輝^1,2、劉明岳¹、吳惠卿^1,2、湯永城³

¹衛生福利部苗栗醫院泌尿科，²中台科技大學，³衛生福利部苗栗醫院檢驗科

Urinary Microbiota Distribution and its relationship with Hunner Lesion

for female patients with Interstitial Cystitis/Bladder Pain Syndrome

Ming-Huei Lee^1,2, Ming Yueh Liu¹, Huei-Ching Wu^1,2, Yung-Cheng Tang³

¹ Department of Urology, Miao-Li Hospital, Ministry of Health&Welfare, Taiwan

²Central Taiwan University of Science and Technology, Taiwan

Purpose: To investigate the potential association of urinary microbiota distribution between  Hunner Lesion (HL) and non-Hunner lesion of female patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) in Taiwan.

Materials and Methods: Female IC/BPS patients were recruited. The midstream urine specimens were collected and examined using the full-length 16S rRNA gene sequencing protocol and informatics to characterize microbial compositional difference between the HL and non-HL subjects (HL). The Shannon's diversity index and the Wilcoxon test were used to analyze the alpha diversity. The beta diversity was detected by Principal Coordinates Analysis and Linear discriminant analysis (LDA) Effect Size (LEfSe) analysis.

Results: A total of 36 female patients with IC/BPS were enrolled for urine microbiota analysis (28 non-HL, aged 52.0±9.6; 8 HL, aged 63.3±4.9).(已修正) Shannon's diversity index showed no significant differences between HL and non-HL female patients (P=0.72). However, we found six species abundances significantly different between female HL and non-HL subjects by LEfSe analysis: Shigella flexneri, Bradyrhizobium embrapense, Prevotella bivia, Enterobacter mori, Veillonella parvula, Pseudomonas brenneri and Cutibacterium acnes. Considering the effect size, we identified that HL female patients are associated with a higher relative abundance of Prevotella bivia and a lower relative abundance of Shigella flexneri.

Conclusions: We found HL female patients with IC/BPS might have two species different with non-HL subjects in the relative abundance of urine microbiota. The results should be challenged in a larger non-biased population. If it is robust, we may use it as an index for prevention or treatment in the future.